Prophylactic Pulmonary Vein Isolation in Typical Atrial Flutter and Heart Failure: a Prospective, Multi-center, Randomized Controlled Study
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 168
- 主要终点
- Composite endpoint of worsening heart failure requiring unplanned hospitalizations or urgent visits, and cardiovascular death
研究概览
简要总结
This study, called the PVI-AFL-HF Trial, investigates two treatments for patients with typical atrial flutter (AFL) and heart failure (HF). It aims to determine whether adding prophylactic pulmonary vein isolation (CPVI) to the standard cavo-tricuspid isthmus (CTI) ablation improves long-term outcomes compared to CTI ablation alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
盲法说明
Follow-up physicians are blinded to treatment allocation
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 80 years
- •Typical AFL referring for ablation
- •No prior history of AF
- •Fulfilling the criteria for HF: New York Heart Association (NYHA) function class II or greater; and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) >125 pg/ml in sinus rhythm or >365 pg/ml in AFL
- •Optimized guideline-directed medical therapy for HF for at least one month
- •A minimum of anticoagulation for three weeks
- •Sign informed consent
排除标准
- •Any AF episodes documented during 48-hour Holter monitoring
- •Presence of left atrial thrombus
- •HF due to infiltrative cardiomyopathy, constrictive pericarditis, active myocarditis, cardiac tamponade, or uncorrected primary valvular disease
- •Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within three months prior to enrollment
- •Previous cardiac transplantation, complex congenital heart disease, rheumatic heart disease
- •Untreated hypothyroidism or hyperthyroidism
- •Dialysis-dependent terminal renal failure
- •Life expectancy <12 months due to non-cardiovascular causes.
- •Any conditions that, in the opinion of the investigator, may render the patient unable to complete the study
- •Female under pregnancy or breast-feeding
- •Involved in other studies
研究组 & 干预措施
CTI-alone arm
干预措施: Cavo-tricuspid isthmus ablation (Procedure)
CTI+CPVI Arm
干预措施: Pulmonary vein isolation plus cavo-tricuspid isthmus ablation (Procedure)
结局指标
主要结局
Composite endpoint of worsening heart failure requiring unplanned hospitalizations or urgent visits, and cardiovascular death
时间窗: From randomization until completion of the planned follow-up, assessed up to 48 months
次要结局
- Change in N-terminal pro-B type natriuretic peptide (NT-proBNP) at one-year(One-year)
- Time to hospitalization or urgent visits for heart failure(From randomization until completion of the planned follow-up, assessed up to 48 months)
- Time to hospitalization for heart failure(From randomization until completion of the planned follow-up, assessed up to 48 months)
- Time to change of diuretics(From randomization until completion of the planned follow-up, assessed up to 48 months)
- Time to urgent visits for heart failure(From randomization until completion of the planned follow-up, assessed up to 48 months)
- Change in New York Heart Association (NYHA) class at one-year(One-year)
- Time to cardiovascular death(From randomization until completion of the planned follow-up, assessed up to 48 months)
- Time to atrial fibrillation recurrence(From randomization until completion of the planned follow-up, assessed up to 48 months)
- Time to all-cause death(From randomization until completion of the planned follow-up, assessed up to 48 months)
- Change in quality of life - Kansas City Cardiomyopathy Questionnaire score (KCCQ-23) at one-year(One-year)
- Change in 6-minute walk test at one-year(One-year)
研究者
Minglong Chen
Dr.
The First Affiliated Hospital with Nanjing Medical University
